BIM

114.2

-1.13%↓

SRT3

229.9

+0.7%↑

GXI

56.85

+2.8%↑

ICAD

20.76

-1.52%↓

BIM

114.2

-1.13%↓

SRT3

229.9

+0.7%↑

GXI

56.85

+2.8%↑

ICAD

20.76

-1.52%↓

BIM

114.2

-1.13%↓

SRT3

229.9

+0.7%↑

GXI

56.85

+2.8%↑

ICAD

20.76

-1.52%↓

BIM

114.2

-1.13%↓

SRT3

229.9

+0.7%↑

GXI

56.85

+2.8%↑

ICAD

20.76

-1.52%↓

BIM

114.2

-1.13%↓

SRT3

229.9

+0.7%↑

GXI

56.85

+2.8%↑

ICAD

20.76

-1.52%↓

Search

Fagron

Atidarymo kaina

SektoriusSveikatos priežiūra

20.2 4.34

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

19.36

Max

20.2

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-298K

40M

Pardavimai

13M

443M

P/E

Sektoriaus vid.

17.164

57.333

Dividendų pajamingumas

1.55

Pelno marža

9.066

Darbuotojai

3,828

EBITDA

-4.3M

71M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+20.59% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.55%

2.63%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-16M

1.4B

Ankstesnė atidarymo kaina

15.86

Ankstesnė uždarymo kaina

20.2

Fagron Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-27 23:55; UTC

Rinkos pokalbiai

Oil Edges Higher Amid Hopes for Easing U.S.-China Trade Tensions -- Market Talk

2025-04-27 23:47; UTC

Rinkos pokalbiai

Gold Falls Amid Dollar Strength, Signs of Easing U.S.-China Trade Tensions -- Market Talk

2025-04-27 23:42; UTC

Rinkos pokalbiai

Nikkei May Rise as Fears About U.S.-China Tensions Ebb -- Market Talk

2025-04-27 23:12; UTC

Uždarbis

Sinopharm Group 1Q Rev CNY141.66B Vs. CNY147.27B >1099.HK

2025-04-27 23:12; UTC

Uždarbis

Sinopharm Group 1Q Net CNY1.46B Vs. Net CNY1.42B >1099.HK

2025-04-27 20:41; UTC

Uždarbis

Pharmaron Beijing 1Q Net CNY305.58M Vs. Net CNY230.56M >300759.SZ

2025-04-27 20:41; UTC

Uždarbis

Pharmaron Beijing: Higher Contributions From Laboratory Services Among Factors Supporting Results> 300759.SZ

2025-04-27 20:41; UTC

Uždarbis

Pharmaron Beijing 1Q Rev CNY3.10B Vs. CNY2.67B >300759.SZ

2025-04-27 18:41; UTC

Svarbiausios naujienos

Bessent Doesn't Know If Trump and Xi Have Talked on Trade -- Barrons.com

2025-04-27 11:00; UTC

Svarbiausios naujienos

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

2025-04-27 05:41; UTC

Uždarbis

China Everbright Bank 1Q Net CNY12.46B Vs. Net CNY12.43B >601818.SH

2025-04-27 05:41; UTC

Uždarbis

China Everbright Bank: Lower Net Interest Income Weighed on Operating Income>601818.SH

2025-04-27 05:41; UTC

Uždarbis

China Everbright Bank 1Q Operating Income CNY33.10B Vs. CNY34.49B>601818.SH

2025-04-27 05:41; UTC

Uždarbis

China Everbright Bank 1Q Impairment Loss on Credit Assets Was CNY8.49B; Down 15.6% on Year>601818.SH

2025-04-27 05:41; UTC

Uždarbis

China Everbright Bank 1Q Operating Expenses Was CNY9.15B; Down 3.2%>601818.SH

2025-04-27 05:41; UTC

Uždarbis

China Everbright Bank 1Q Net Interst Income Was CNY22.54B; Down 6.8% on Year>601818.SH

2025-04-27 05:34; UTC

Uždarbis

Chongqing Rural Commercial Bank: 1Q Results Supported by Higher Net Interest Income>3618.HK

2025-04-27 05:34; UTC

Uždarbis

Chongqing Rural Commercial Bank 1Q Operating Income CNY7.22B Vs. CNY7.13B>3618.HK

2025-04-27 05:34; UTC

Uždarbis

Chongqing Rural Commercial Bank 1Q Net CNY3.75B Vs. Net CNY3.52B >3618.HK

2025-04-27 05:29; UTC

Uždarbis

China Shenhua Energy: Results Weighed by Fall in Selling Prices of Coal >1088.HK

2025-04-27 05:29; UTC

Uždarbis

China Shenhua Energy 1Q Net CNY13.37B Vs. Net CNY17.76B >1088.HK

2025-04-27 05:29; UTC

Uždarbis

China Shenhua Energy 1Q Rev CNY69.59B Vs. CNY87.65B >1088.HK

2025-04-27 05:29; UTC

Uždarbis

China Shenhua Energy: Lower Revenue From Electricity Sales Also Hurt Results >1088.HK

2025-04-27 05:21; UTC

Uždarbis

CMOC Group 1Q Net CNY3.95B Vs. Net CNY2.07B >3993.HK

2025-04-27 05:21; UTC

Uždarbis

CMOC Group: Cost Cuts Also Among Factors that Boosted 1Q Net >3993.HK

2025-04-27 05:21; UTC

Uždarbis

CMOC Group 1Q Rev CNY46.01B Vs. CNY46.12B >3993.HK

2025-04-27 05:21; UTC

Uždarbis

CMOC Group: Increase in Prices of Copper, Cobalt Supported Results>3993.HK

2025-04-27 03:00; UTC

Svarbiausios naujienos

Chinese Manufacturers Are Scouring the World for New Buyers -- WSJ

2025-04-27 00:30; UTC

Svarbiausios naujienos

Meta's 'Digital Companions' Will Talk Sex With Users -- Even Children -- WSJ

2025-04-27 00:30; UTC

Svarbiausios naujienos

Meta's 'Digital Companions' Will Talk Sex With Users -- Even Children -- WSJ -2-

Akcijų palyginimas

Kainos pokytis

Fagron Prognozė

Kainos tikslas

By TipRanks

20.59% į viršų

12 mėnesių prognozė

Vidutinis 19.5 EUR  20.59%

Aukščiausias 19.5 EUR

Žemiausias 19.5 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fagron kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.